-
1
-
-
33644843721
-
The use of MRI as an outcome measure in clinical trials
-
Li DK, Li MJ, Traboulsee A, Zhao G, Riddehough A, Paty D. The use of MRI as an outcome measure in clinical trials. Adv Neurol 2006;98:203-226.
-
(2006)
Adv Neurol
, vol.98
, pp. 203-226
-
-
Li, D.K.1
Li, M.J.2
Traboulsee, A.3
Zhao, G.4
Riddehough, A.5
Paty, D.6
-
2
-
-
0035091667
-
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
-
and European/Canadian Glatiramer Acetate Study Group
-
Comi G, Filippi M, Wolinsky JS, and European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-297.
-
(2001)
Ann Neurol
, vol.49
, pp. 290-297
-
-
Comi, G.1
Filippi, M.2
Wolinsky, J.S.3
-
3
-
-
0030773332
-
Characterization of MRI response to treatment with interferon beta-1b: Contrast-enhancing MRI lesion frequency as a primary outcome measure
-
Stone LA, Frank JA, Albert PS, et al. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 1997;49:862-869.
-
(1997)
Neurology
, vol.49
, pp. 862-869
-
-
Stone, L.A.1
Frank, J.A.2
Albert, P.S.3
-
4
-
-
0037069306
-
Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses
-
Rovaris M, Codella M, Moiola L, et al. Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses. Neurology 2002;59:1429-1432.
-
(2002)
Neurology
, vol.59
, pp. 1429-1432
-
-
Rovaris, M.1
Codella, M.2
Moiola, L.3
-
5
-
-
2442561768
-
Oral simvastatin treatment in relapsing-remitting multiple sclerosis
-
Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004;363:1607-1608.
-
(2004)
Lancet
, vol.363
, pp. 1607-1608
-
-
Vollmer, T.1
Key, L.2
Durkalski, V.3
-
6
-
-
84970857770
-
Regression towards the mean
-
Bland JM, Altman DG. Regression towards the mean. BMJ 1994;308:1499.
-
(1994)
BMJ
, vol.308
, pp. 1499
-
-
Bland, J.M.1
Altman, D.G.2
-
7
-
-
84970851084
-
Some examples of regression towards the mean
-
Bland JM, Altman DG. Some examples of regression towards the mean. BMJ 1994;309:780.
-
(1994)
BMJ
, vol.309
, pp. 780
-
-
Bland, J.M.1
Altman, D.G.2
-
8
-
-
6944249912
-
Biomarkers and surrogate outcomes in neurodegenerative disease: Lessons from multiple sclerosis
-
Miller DH. Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx 2004;1:284-294.
-
(2004)
NeuroRx
, vol.1
, pp. 284-294
-
-
Miller, D.H.1
-
9
-
-
5644300578
-
Disease-modifying therapy in MS: A critical review of the literature. Part I: analysis of clinical trial errors
-
Goodin DS. Disease-modifying therapy in MS: a critical review of the literature. Part I: analysis of clinical trial errors. J Neurol 2004;251(suppl 5):v3-v11.
-
(2004)
J Neurol
, vol.251
, Issue.SUPPL. 5
-
-
Goodin, D.S.1
-
10
-
-
0345601517
-
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis
-
PRISMS Study Group
-
PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998;352:1498-1504.
-
(1998)
Lancet
, vol.352
, pp. 1498-1504
-
-
-
11
-
-
0032864616
-
Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon- β1a in relapsing-remitting multiple sclerosis
-
Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon- β1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999;46:197-206.
-
(1999)
Ann Neurol
, vol.46
, pp. 197-206
-
-
Li, D.K.1
Paty, D.W.2
-
12
-
-
0040647877
-
The multivariate Poisson-log normal distribution
-
Aitchison J, Ho CH. The multivariate Poisson-log normal distribution. Biometrika 1989;76:643-653.
-
(1989)
Biometrika
, vol.76
, pp. 643-653
-
-
Aitchison, J.1
Ho, C.H.2
-
14
-
-
0027418515
-
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
-
IFNB Multiple Sclerosis Study Group
-
IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1996;43:655-661.
-
(1996)
Neurology
, vol.43
, pp. 655-661
-
-
-
15
-
-
0029082566
-
Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial
-
Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-1276.
-
(1995)
Neurology
, vol.45
, pp. 1268-1276
-
-
Johnson, K.P.1
Brooks, B.R.2
Cohen, J.A.3
-
16
-
-
0008678962
-
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
-
Lawrence JD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
-
(1996)
Ann Neurol
, vol.39
, pp. 285-294
-
-
Lawrence, J.D.1
Cookfair, D.L.2
Rudick, R.A.3
-
17
-
-
33846271831
-
Regression to the mean in multiple sclerosis
-
Martinez-Yelamos S, Martinez-Yelamos A, Martin Ozaeta, Casado V, Carmona O, Arbizu TX.. Regression to the mean in multiple sclerosis. Mult Scler 2006;12:826-829.
-
(2006)
Mult Scler
, vol.12
, pp. 826-829
-
-
Martinez-Yelamos, S.1
Martinez-Yelamos, A.2
Ozaeta, M.3
Casado, V.4
Carmona, O.5
Arbizu, T.X.6
|